AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration

"This collaboration is the first for Harpoon and highlights the high level of industry interest in best-in-class platform technologies. We are excited about partnering with AbbVie to help generate novel T-cell engagers for the treatment of cancer based on the combination of T-cell receptors with TriTACs," said Jerry McMahon, Ph.D., chief executive officer, Harpoon Therapeutics.

• Source: finance.yahoo
• 682
• October 23, 2017